Upstream Bio’s Verekitug Shows Promise in CRSwNP Phase II Trial

Upstream Bio’s TSLP-targeting monoclonal antibody, verekitug, achieved both primary and secondary endpoints in the Phase II VIBRANT study for chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated a statistically significant 1.8-point placebo-adjusted reduction in endoscopic nasal polyp scores (NPS) from baseline.

Verekitug, administered once every 12 weeks, also reduced congestion scores by 0.8 and lowered the need for surgery or systemic corticosteroid use by 76%, including in patients with prior corticosteroid therapy or surgical history. The data positions verekitug competitively against AstraZeneca and Amgen’s Tezspire, which requires more frequent dosing.

Upstream Bio plans a longer trial to further evaluate verekitug in CRSwNP and will engage global regulatory authorities regarding its development. The company is also exploring a 24-week dosing schedule based on results from the Phase II VALIANT severe asthma trial. If approved, verekitug would enter a competitive CRSwNP market alongside Dupixent, Nucala, Xolair, and Tezspire.

08-09-2025